Paul Pyzowski, CEO, is an entrepreneur and executive whose career has spanned healthcare, life sciences, neurotherapeutics, DNA sequencing, and computer science. He founded Altimate: The Precision Psychiatry Company, to apply data science to behavioral health to transform the care of these patients.
Paul was the founding CEO of Aleva Neurotherapeutics, a Swiss-based company that recently received EU approval for the most advanced deep brain stimulation (DBS) system on the market. He has served as an executive at several MIT spinout companies, including ANDE, which developed the only US government approved field-use product for human DNA identification. He also worked closely with the founders of Neuroelectrics, guiding their therapy for pediatric epilepsy through a succesful FDA clinical study.
Paul also has experience in the US healthcare provider market, having managed a hundred-person clinical laboratory assisting physicians treating pain and addiction. He started his career in computational physics as a VP and executive officer at Ansoft (NASDAQ: ANST). He has a BSEE from Carnegie-Mellon, and an MBA from IMD in Lausanne.
Dr. Valerie Photos, Chief Medical Officer is a pioneer in multiple sectors of behavioral health innovation, with over a decade of experience at Harvard Medical School and affiliated private clinics in the adoption of health technologies. Valerie received her PhD in Clinical Science from Harvard, postdoctoral training in Clinical Psychology from Harvard Medical School, and fi nance education from the University of Chicago.
Dr. Wasim Q. Malik, Director, is the Managing Partner at Iaso Ventures. He previously served as Chief Digital Strategist at Roivant Sciences, where he built the digital health strategy and investments business to help accelerate drug development and commercialization across 15+ therapeutic areas. Wasim has served on the faculty at Harvard Medical School and Massachusetts General Hospital, where he built a research program on tech-enabled clinical research in neurology.
Wasim currently serves on the board of directors at Saphetor and Altimate Health, on the business advisory board of the Epilepsy Foundation, as a Senior Advisor at Health Catalyst, and on several startup advisory boards. He has published over 100 research papers and patents. He received his Doctor of Philosophy in electrical engineering from Oxford, postdoctoral training in neuroscience from MIT, and executive education in venture capital and private equity from Harvard Business School.